Paul A. Gurbel, MD: March 21, 2019




Paul A. Gurbel, MD, FACC

Director of Interventional Cardiology and Cardiovascular Medicine Research and Professor of Medicine at Johns Hopkins School of Medicine

Just this week the American College of Cardiology and the American Heart Association made changes to their guideline for the use of aspirin to prevent first heart attacks, strokes and heart failure, which is primary prevention. This update has led to confusion among doctors and the general public about the preventative use of aspirin.

Some people take aspirin because they’ve already had a cardiovascular event like a heart attack or ischemic stroke, which is secondary prevention. In the U.S., aspirin is indicated for secondary prevention. The guidelines do not change the importance of aspirin for these patients. For these people, aspirin could be a life-saving preventative treatment. For people who haven’t had a heart attack or stroke, the new guidelines are still supportive of the use of aspirin for certain individuals based on their personal health risks and overall assessments.

Based on its proven efficacy, safety and cost-effectiveness, aspirin is widely recognized as one of the preeminent antiplatelet therapies of choice across a wide cardiovascular risk continuum. No one should start, stop or modify an aspirin regimen without first speaking with their doctor.

On Thursday, March 21st, interventional cardiologist, Dr. Paul Gurbel, is available to discuss the changes in these guidelines and provide more information around the preventative use of aspirin.

For more information, visit:



Paul A. Gurbel, MD, world-renowned interventional cardiologist and researcher, is the the Director of Interventional Cardiology and Cardiovascular Medicine Research at Inova Heart and Vascular Institute (IHVI), located on the Inova Fairfax Medical Campus.  Prior to that, Dr. Gurbel was at Sinai Hospital of Baltimore, where he served as the Director of Cardiovascular Research and the Director of the Sinai Center for Thrombosis Research, which he founded in 1997. He is also a Professor of Medicine at the Johns Hopkins University School of Medicine and Adjunct Professor of Medicine at Duke University School of Medicine. Dr. Gurbel’s research focuses on the effects and development of antiplatelet agents. His laboratory pioneered the concept of antiplatelet response variability, and his research and observations led to the development of new P2Y12 inhibitors. Dr. Gurbel’s lab also instituted personalized antiplatelet therapy based on phenotypic and genetic analyses. He holds patents in the fields of interventional cardiology and antithrombotic therapy. Dr. Gurbel earned his medical degree at the University of Maryland School of Medicine and completed an internship and residency in Internal Medicine at Duke University Medical Center. He then completed a fellowship in Pulmonary and Critical Care at Johns Hopkins University, followed by fellowships in Cardiovascular Disease and Interventional Cardiology as well as a Chief Residency in internal medicine at Duke. He is board-certified in internal medicine, cardiovascular disease and interventional cardiology by the American Board of Internal Medicine.

Speak Your Mind